City Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Latest news
All CTY news ›CitroTech Inc. Announces Pricing of $5.6 Million Public Offering
CitroTech Inc. (NYSE AM: CITR) ("CitroTech" or the "Company"), a specialty chemical company developing environmentally responsible fire-inhibitor solutions, today announced the pricing of an underwritten public offering of 2,240,000 shares…
More from 1 other outlet
City Therapeutics (NASDAQ:CTY) Stock Falls 6.3% – Here’s What Happened
City Therapeutics, Inc. (NASDAQ:CTY – Get Free Report) fell 6.3% during trading on Tuesday. The stock traded as low as $19.54 and last traded at $19.57. 195,631 shares changed hands during mid-day trading, a decline of 23% from the average…
Bambusa Therapeutics Announces Pricing of Upsized Initial Public Offering
BOSTON, Oct. 29, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Nasdaq: BBTX) ('Bambusa Therapeutics' or 'Bambusa'), a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies for…
Aspen Neuroscience prices IPO at $15 per share
Aspen Neuroscience (ASPE) priced its IPO of 9.375M shares at $15 per share, expecting gross proceeds of ~$140.6M. - Aspen Neuroscience (ASPE) priced its IPO of 9.375M shares at $15 per share, expecting gross proceeds of ~$140.6M. - The…
INmune Bio, Inc. Announces Pricing of $4.50 Million Registered Direct Offering and Concurrent Private Placement
A.G.P./ Alliance Global Partners is acting as the sole placement agent for the Offering. A prospectus supplement relating to the registered direct offering and the accompanying prospectus will be filed with the SEC and will be available on…
Aspen Neuroscience (ASPE) sets $15-$17 IPO range for $150 million Parkinson's cell therapy raise
As seen on the 24/7 Wall St. homepage on October 26, 2026. Second amendment sets $15-$17 range on a $150 million deal Aspen Neuroscience penciled in a $15 to $17 range on 9.375 million shares, a roughly $150 million Nasdaq raise for its…
City Therapeutics (NASDAQ:CTY) Stock Moved Up to Hold by Wall Street Zen
Wall Street Zen upgraded shares of City Therapeutics (NASDAQ:CTY – Free Report) to a hold rating in a research report released on Saturday morning,Wall Street Zen reports. City Therapeutics Price Performance Shares of CTY stock opened at…
After tax other income/expense of TAHO Pharmaceuticals Ltd – TWSE:6467
Taho Pharmaceuticals Ltd. engages in the research and development of pharmaceutical products. Its Technology Platform products are the Transepithelial Delivery System, Transdermal DDS, Transmucosal SSD, and Bio-Revie. The firm's Research &…
Operating expenses (excl. COGS) of TAHO Pharmaceuticals Ltd – TWSE:6467
Taho Pharmaceuticals Ltd. engages in the research and development of pharmaceutical products. Its Technology Platform products are the Transepithelial Delivery System, Transdermal DDS, Transmucosal SSD, and Bio-Revie. The firm's Research &…
ARCH Venture Fund XII Converts Preferred Shares to Common Stock at City Therapeutics IPO
Kalkine Media Did Stronger Steel Earnings Put Nucor (NYSE:NUE) in Focus? Did Stronger Aluminum Earnings Put Alcoa (NYSE:AA) in Focus? ARCH Venture Partners XII, LLC and affiliated reporting persons disclosed the
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- tradingview.com21
- stocktitan.net12
- seekingalpha.com3
- biospace.com2
- globenewswire.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 65 articles, not a forecast.